Foghorn Therapeutics Inc. reports results for the quarter ended in June - Earnings Summary

Foghorn Therapeutics

09/08/2023 13:01

* Foghorn Therapeutics Inc.  FHTX.OQ  reported a quarterly
adjusted loss of 70 cents​​ per share for the quarter ended in
June. The mean expectation of four analysts for the quarter was
for a loss of 73 cents per share.
    * Revenue rose 24.7% to $5.60 million from a year ago;
analysts
expected $6.26 million. 
    * Foghorn Therapeutics Inc.'s reported EPS for the quarter
was a
loss of 70 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Foghorn Therapeutics Inc. shares had risen by 31.4% this
quarter and gained 45.0% so far this year.
    * The company reported a quarterly loss of $29.49 million.
    * Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $15.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 12:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.73          -0.70          Beat
 Mar. 31 2023      -0.72          -0.73          Missed
 Dec. 31 2022      -0.62          -0.69          Missed
 Sep. 30 2022      -0.62          -0.62          Met